Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 713-723

  Segal, Jack L ^a   Pathak, Mayank S ^a   Hernandez, Jesus P ^a   Himber, Peter L ^a   Brunnemann, Sherry R ^a   Charter, Richard S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NERVOUSNESS; RANDOMIZED CONTROLLED TRIAL; SENSORIMOTOR FUNCTION; SPINAL CORD INJURY; TREATMENT OUTCOME; VERTIGO;

4-AMINOPYRIDINE; ADMINISTRATION, ORAL; ADULT; AGED; CENTRAL NERVOUS SYSTEM; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNEL BLOCKERS; PSYCHOMOTOR PERFORMANCE; SPINAL CORD INJURIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033000481     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.713.31540     Document Type: Article

References (37)

1. Breasted JH, ed. Case thirty-one. First description of quadriplegia. Case of dislocation of cervical vertebra. Circa 3000 B.C. In: The Edwin Smith surgical papyrus. Chicago: University of Chicago Press, 1930.
2. Segal JL, Brunnemann SR. 4-Aminopyridine improves pulmonary function in quadriplegic humans with long-standing spinal cord injury. Pharmacotherapy 1997;17(3):415-23.
3. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993;19:1-18.
4. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21.
5. Bunge RP, Puckett WR, Bercerra JL, Marcillo A, Quencer RM. Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. In: Seil FJ, ed. Advances in neurology, vol 59. New York: Raven Press, 1993:75-89.
6. Blight AR, DeCrescito V. Morphometric analysis of experimental spinal cord injury in the cat: the relation of injury intensity to survival of myelinated axons. Neuroscience 1986;19:321-41.
7. Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77(2):553-62.
8. Bostock H, Sears TA, Sheratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibers. J Physiol 1991;313:301-15.
9. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-8.
10. Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358-61.
11. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurologic deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991;8:103-9.
12. Potter PJ, Hayes KC, Hsieh JTC, Delaney GA, Segal JL. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998;36:147-55.
13. Noordenbos W, Wall PD. Diverse sensory functions with an almost totally divided spinal cord. A case of spinal cord transection with preservation of part of one anterolateral quadrant. Pain 1976;2:185-95.
14. Young W. Recovery mechanisms in spinal cord injury: implications for regenerative therapy. In: Seil FJ, ed. Neural regeneration and transplantation. New York: AR Liss, 1988:157-69.
15. Potter PJ, Hayes KC, Segal JL, et al. Randomized double-blind crossover trial of Fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998;15(10):837-49.
16. Joyce CRB. Placebos and other comparative treatments. Br J Clin Pharmacol 1982;13:313-18.
17. American Spinal Injury Association-International Medical Society of Paraplegia. International standards for neurological and functional classification of spinal cord injury, 4th ed. Chicago: American Spinal Injury Association, 1996.
18. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
19. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696-702.
20. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2):206-7.
21. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-2.
22. Gibbons JD, ed. Nonparametric statistical inference, 2nd ed. New York: Marcel Dekker, 1985.
23. Segal JL, Brunnemann SR. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med 1998;21:200-4.
24. Segal JL, Brunnemann SR. The effects of 4-aminopyridine on heart rate and heart rate variability in humans with spinal cord injury. J Spinal Cord Med 1997;20(1):163.
25. Crozier KS, Graziani V, Ditunno JF Jr, Herbison GJ. Spinal cord injury: prognosis for ambulation based on sensory examination in patients who are initially motor complete. Arch Phys Med Rehabil 1991;72(2):119-21.
26. Williams W, Apstein M, Chassin S, et al. Gallbladder motility in spinal cord injury patients. J Nucl Med 1987;28:P596.
27. Segal JL, Brunnemann SR, Eltorai IM, Vulpe M. Decreased systemic clearance of lorazepam in humans with spinal cord injury. J Clin Pharmacol 1991;31:651-6.
28. Milne N, Segal JL, Rypins EB, Brunnemann SR, Lyons KP. Biliary kinetics in spinal cord injury (SCI). J Nucl Med 1987;28:688.
29. Segal JL, Milne N, Brunnemann SR. Gastric emptying is impaired in patients with spinal cord injury. Am J Gastroenterol 1995;90(3):466-70.
30. Bluechardt MH, Wiens M, Thomas SG, Plyley MJ. Repeated measurements of pulmonary function following spinal cord injury. Paraplegia 1992;30:768-44.
31. Roth EJ, Lu A, Primack S, Oken J, et al. Ventilatory function in cervical and high thoracic spinal cord injury. Relationship to level of injury and tone. Am J Phys Med Rehabil 1997;76(4):262-7.
32. Bergofsky EE. Mechanism for respiratory insufficiency after cervical cord injury: a source of alveolar hypoventilation. Ann Intern Med 1964;61:435-7.
33. Dietz V, Wirz M, Jensen L. Locomotion in patients with spinal cord injuries. Phys Ther 1997;77(5):508-16.
34. Jankowska E, Lundberg A, Rudomin P, Sykova E. Effects of 4-aminopyridine on synaptic transmission in the cat spinal cord. Brain Res 1982;240:117-29.
35. Molgo J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmissions and the effect of pH changes. Eur J Pharmacol 1980;61:25-34.
36. Gumbleton M, Sneader W. Pharmacokinetic considerations in rational drug design. Clin Pharmacokinet 1994;26(3):161-8.
37. van Diemen HAM, Polman CH, Koetsier JC, et al. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum levels related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204.